Our process includes: Comprehensive medical evaluation and blood work Personalized peptide and hormone protocol Ongoing patient education and progress tracking Safe compounding sources and follow up care Through this evidence based approach, our patients achieve improvements in energy, body composition, mental clarity, and overall wellness
The differential susceptibility of various immune cells to ferroptosis determines their roles in iron homeostasis and antioxidant defense
Ipamorelin and Bone Mineral Content Research In 13-week-old female Sprague-Dawley rats treated continuously for 12 weeks, Ipamorelin increased bone mineral content as measured by dual X-ray absorptiometry (DXA), with pQCT analysis showing the increase in cortical BMC was attributable to increased cross-sectional bone area rather than changes in volumetric bone mineral density
2 way Dual Activation GHRH-R (CJC-1295) + GHS-R1a (Ipamorelin) two complementary pituitary targets 2-4x GH AUC Demonstrated Synergy Area under the GH curve 2 to 4 times greater than each peptide in monotherapy 5.8 - 8.1 days CJC-1295 Half-Life Sustained elevation of IGF-1 for 9 to 11 days after a single injection 10 mg Pre-formulated mix 5 mg CJC-1295 (No DAC) + 5 mg Ipamorelin per vial | Purity 99% HPLC Selective Hormonal Profile Ipamorelin: no increase in cortisol, prolactin or ACTH (Raun et al., 1998) Mechanism of Action Dual-Channel Synergy Simultaneous activation of GHRH-R and GHS-R1a for amplified GH stimulation GHRH Lane CJC-1295 GHRH Analog (Mod GRF 1-29) A synthetic peptide of 29 amino acids that selectively binds to the GHRH receptor on pituitary somatotroph cells
They are not intended to diagnose or treat medical conditions
